#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians treating patients with non-alcoholic fatty liver disease or metabolic syndrome now have preliminary evidence that CBD and CBG may offer therapeutic benefit beyond current standard treatments, potentially expanding the pharmacologic toolkit for these increasingly common conditions. This research could inform discussions with patients about cannabis-derived compounds as adjunctive therapy, though clinicians should note that human clinical trials are still needed before recommending these compounds outside of research settings. Understanding cannabinoid effects on metabolic pathways helps clinicians better counsel patients who are already self-medicating with cannabis products and provide evidence-based guidance on efficacy and safety.
A preclinical study demonstrates that cannabidiol (CBD) and cannabigerol (CBG) may offer therapeutic potential for non-alcoholic fatty liver disease by improving glycemic control and reducing lipid levels associated with hepatic steatosis. These findings suggest a novel mechanistic pathway through which cannabinoids could address multiple metabolic abnormalities underlying fatty liver disease, a condition with limited pharmacological options that affects a substantial portion of the population. While the results are promising, clinicians should recognize this as early-stage research requiring validation in human trials before considering cannabis-derived compounds as part of standard management protocols. The work highlights the importance of continued investigation into cannabinoid pharmacology for metabolic and hepatic disorders, particularly given the growing prevalence of fatty liver disease and the need for effective interventions. For now, patients with fatty liver disease should continue following evidence-based recommendations including weight loss, exercise, and management of underlying metabolic conditions, while clinicians can monitor emerging clinical trial data on cannabinoid therapeutics in this space.
“What we’re seeing in the preclinical data with CBD and CBG is metabolic improvement at the cellular level, which is exactly what patients with fatty liver disease need, but we have to be honest that animal studies don’t yet tell us the dose, duration, or real-world efficacy in humans, so my advice to patients remains to optimize weight, reduce refined carbohydrates, and exercise while we wait for the clinical trials that would actually inform practice.”
💊 While preclinical findings showing that cannabidiol (CBD) and cannabigerol (CBG) improve metabolic markers in fatty liver disease models are intriguing, clinicians should recognize that in vitro and animal studies often fail to translate to human efficacy and safety, and currently available cannabis products lack standardization and rigorous clinical trial data in humans with nonalcoholic fatty liver disease. The study does not address critical practical questions about optimal dosing, long-term safety, potential drug interactions with common medications, or how cannabis compounds would compare to established interventions like lifestyle modification and the emerging pharmacotherapies in development. Given that our patients with metabolic dysfunction-associated fatty liver disease already have evidence-based options (weight loss, exercise, pioglitazone, GLP-1 receptor agonists), recommending cannabis products outside of a clinical trial remains premature and may delay patients from pursuing proven strategies. Until well-
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: